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IN-DEPTH BIOINFORMATICS ANALYSIS OF THE PHOSPHOPROTEOME OF 
TRIPLE NEGATIVE BREAST CANCER TREATED WITH A TUMOR SELECTIVE 
NQO1 BIOACTIVATABLE DRUG 
The main focus of this study is to elucidate changes in the proteome of triple 
negative breast cancer cells in response to a novel bioactivated anti-cancer agent IB-DNQ 
(isobutyl-deoxyniboquinone). NQO1 or NADPH:quinone oxidoreductase-1 is a 
detoxifying enzyme overexpressed in many solid tumors and low expression in normal 
cells. IB-DNQ is bio-activated by NQO1 enzyme via a futile redox cycling, producing 
large amounts of reactive oxygen species (ROS) in the process, which causes DNA lesions 
in cancer cells. The status of NQO1 is important for the IB-DNQ mediated cancer cell 
death. 
IB-DNQ mediated therapy has great potency in killing breast cancer cells compared 
to PARP inhibitor Rucaparib. From this proteomics study, large changes in 
phosphorylation are observed in utilizing a combination therapy with low dose of IB-DNQ 
and PARP inhibitor Rucaparib. Protein phosphorylation events within the transcription 
machinery and DNA damage repair pathways are changed upon drug treatment.  
Computational and bioinformatic analysis of kinases involved through kinase 
substrate enrichment analysis revealed changes in downstream signaling of cell cycle 
checkpoint proteins. CDK1 and CDK2 substrate phosphorylation was decreased in 
response to combination drug therapy. Based on the differential kinase activity as 
determined by substrate abundance, we hypothesize that since CDK1/2 plays an important 
role in DNA damage repair via the homologous recombination pathway, its 
vii 
downregulation further abrogated double stranded break repair in BRCA deficient cells 
creating a state of “BRCAness”, leading to heightened sensitivity to the PARP inhibitor 
Rucaparib. These studies give insight into the mechanism of IB-DNQ action as an 
anticancer agent.  
 
Amber L. Mosley, Ph.D., Chair 
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In living systems, functions are carried out by proteins and deregulation of these proteins 
associated with various functional pathways, are responsible for many diseases including 
cancer. Worldwide, cancer is responsible for almost ten million deaths annually and the 
burden is increasing due to poor clinical outcome, drug resistance, tumor heterogeneity, 
late diagnosis, disease relapse and failed clinical trials [1]. The wealth of information 
generated by large scale genomic data and lowering costs of Next Generation Sequencing 
(NGS) technologies has helped the scientific community to understand the underlying 
genetic causes of cancer [2]. To date, genomic and transcriptomic studies have helped us 
to understand many differences in cancer cells caused by genetic variation including copy 
number changes, gene mutations, and differential gene expression associated with specific 
disease subtypes that contribute to disease pathology [3]. But there has been limited success 
in translating this information from the bench to the clinic to develop efficient therapeutics 
[4]. For a systems level disease like cancer, understanding the mechanism of disease 
progression and cellular signaling changes is important and needs to be studied at the 
protein and signaling levels. Moreover, the drugs approved for cancer therapy target at the 
protein level and not at the gene level [5]. The regulation of protein function, degradation, 
localization and post-translational modifications (PTMs) play a critical role in disease 
progression and diagnosis [6]. PTMs are covalent modifications that change the properties 
of an amino acid or protein.  They reversibly or irreversibly alter the structure and 
functional properties of a protein through biochemical reactions [7]. Various types of PTMs 
like phosphorylation, glycosylation, acetylation, methylation and ubiquitination are 
identified [8]. These changes happen downstream of gene expression, and transcript 
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expression measured from NGS studies do not correlate with the protein abundance present 
in cells.   Phosphorylation is a post-translational modification that relays external stimuli 
through a cascade of signaling events to elicit appropriate biological responses [7]. With 
the emergence of Mass Spectrometry (MS) based technology, we are able to quantify 
protein abundance and identify PTMs like phosphorylation by identifying characteristic 
mass differences between modified and unmodified peptide [9]. Phosphoproteome studies 
have become an important tool in precision medicine to characterize the role of kinases 
and phosphatases in disease progression, and are targeted  for disease therapy by small 
molecule inhibitors of protein kinases and related molecules [10].  
Phosphorylation is mediated by protein kinases which transfer the gamma 
phosphate group from ATP to specific amino acids, mainly Serine (Ser), Threonine (Thr) 
or Tyrosine (Tyr) residues [11]. Every phosphorylation event adds a mass of 80 Daltons to 
the total mass of the peptide. The changes in phosphorylation can be studied by mass 
spectrometry by measuring the mass difference of the phosphorylated residues on the 
peptides to determine the site of phosphorylation on the protein and understand the 
functional consequences of that modification [12]. This new layer of information must be 
integrated with other omics studies to capture the functional state and dynamic properties 
of a cell. 
In this study, MS based phosphoproteome analysis is performed on Triple Negative 
Breast Cancer (TNBC) cells upon treatment with NAD(P)H Quinone Dehydrogenase 1 
(NQO1) bioactivable drug, isobutyl-deoxynyboquinone (IB-DNQ) and Poly (ADP-ribose) 
polymerase (PARP) inhibitor Rucaparib. NQO1 gene encodes NAD(P)H dehydrogenase 
enzyme in humans [13]. It is a FAD binding protein that functions as a homodimer and 
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catalyzes two electron reduction of toxic quinones to hydroquinones (HQ) [14]. The HQ 
binds to glutathione forming intracellular HQ-GSH conjugate that can be excreted from 
the cells [12] (Picture 1). The enzyme works with equal efficiency with both cofactors 
NADH and NADPH and requires a tightly bound FAD cofactor [15]. Certain compounds 
such as antitumor quinones can be bioactivated via the two electron reduction by NQO1 
[16]. Because of the high levels of NQO1 in certain tumors, this has led to an interest in 
designing compounds that can be bioactivated by NQO1 as antitumor agents [17]. 
 
 
Picture 1: The reaction catalyzed by NQO1 in which a quinone is reduced to a 
hydroquinone by the NADH or NADPH 
 
IB-DNQ is a deoxyniboquinone compound that is dependent on NQO1 for its activation 
and therefore is bioactivated by NQO1. NQO1 performs a two-electron reduction of the 
parent IB-DNQ to its HQ form, which is unstable, the HQ spontaneously reverts back to 
its parental, oxidized form through two reactions with molecular oxygen, the intermediate 
being a semiquinone (SQ) [18]. This futile cycle generates two superoxide moieties which 
eventually generate massive H2O2 concentration, which carry out DNA damage and ER 
Ca2+ release [19] (Figure 1). 
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Figure 1: NQO1 mediated bioactivation of IB-DNQ 
 
NQO1 is overexpressed in various types of solid cancers including breast cancer while 
catalase is overexpressed in normal cells [20]. In normal cells, the H2O2 produced by NQO1 
mediated IB-DNQ activation is removed by catalase and they are protected. While in 
cancer cells, the absence of catalase causes accumulation of H2O2 leading to DNA damage, 
activation of cell cycle checkpoint machinery, PARP1 hyperactivation that causes 
depletion of NAD+/ATP, mitochondrial dysfunction, and apoptosis inducing factor (AIF) 
release resulting in tumor selective cell death [21]. The absence or low abundance of 
catalase is a property of cancer cells is used to selectively target them with NQO1 
bioactivatable compounds using a precision medicine approach [20]. Patients with reduced 
expression of NQO1 or with single nucleotide polymorphism (SNP) in NQO1 show 
resistance to chemotherapeutic drugs and particularly NQO1 bioactivatable compounds. 
There are two known SNP’s in NQO1, namely NQO1 type 2 (NQO1*2) and NQO1 type 
3 (NQO1*3). The NQO1*2 polymorphism containing C609T change leads to proline to 
serine substitution at position 187 of NQO1.[22] This mutant protein is catalytically 
5 
inactive due to its reduced ability to bind the FAD cofactor [23] and its catalytic activity is 
only 4% compared to wild type [24]. The NQO1*3 polymorphism with C465T change 
leads to arginine to tryptophan substitution in the protein; this substitution results in a 
change in rate of quinone substrate metabolism. The type 2 polymorphism is most common 
[25]. The NQO1 status of cancer cells is important for the IB-DNQ treatment to work. 
Patients with NQO1 polymorphism will not show the desired effects with IB-DNQ 
treatment [26]. 
Previous studies with another bioactivable drug beta-lapachone showed synergistic 
action with PARP inhibitors. [27] BRCA and PARP are housekeeping genes involved in 
DNA damage repair via the homologous recombination (HR) pathway. Healthy cells 
having two normal copies of BRCA1 and BRCA2, will have no effect from PARP inhibitor 
as the cells still have BRCA working in them [28]. BRCA mutated cells with single-
stranded breaks can still use PARP to fix the DNA break [29]. Whereas in cancer cells with 
the loss of both copies of BRCA, there will be an impaired HR pathway, which eventually 
will lead to cell death by PARP inhibitors [30]. Likewise, the double-stranded break (DSB) 
induced by very high doses IB-DNQ will be difficult to repair by HR deficient cancer cells. 
This synergistic action of IB-DNQ mediated DSB and cell death by PARP inhibitor 
Rucaparib is exploited in TNBC with minimum off-target effects. 
Proteomics datasets are characterized by the wide heterogeneity commonly found 
in biological samples making it difficult to identify important biomarkers [9]. The first step 
in omics data analysis approach is to identify affected biological processes and functions 
from differentially expressed proteins between disease and normal states using various 
computational tools like Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA). 
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The MS based phosphoproteomic study only provides information about the 
phosphorylated residues in the protein but no functional information about the kinases 
affecting those phosphorylation events. Here, we used a kinase prediction tool called 
Kinase Substrate Enrichment Analysis (KSEA) to predict the kinases involved in the 
phosphorylation events and to understand the mechanism of drug action in terms of 
changes in cell signaling. This information can be mapped onto protein-protein interaction 
(PPI) network and kinase-substrate interaction networks to provide a better picture of the 
effect of perturbation in a given biological network (Figure 2). 
 











Proteomics of Patient-Derived TNBC Cells 
This phosphoproteomic study utilized MDA-MB-231 cells which are NQO1*2 
polymorphic human metastatic TNBC cells, in replicates of three. The NQO1 positive cells 
were created by overexpressing NQO1 by plasmid transfection. It is likely that 
overexpressed NQO1 maybe substantial amount higher than endogenous expression 
however overexpression is consistent with previously shown work which indicates 
overexpression of NQO1 in many solid cancers [31]. Both NQO1 positive and NQO1 
negative cells were treated for 4 hours with IB-DNQ 0.1 µM (sublethal dose), IB-DNQ 0.4 
µM (lethal dose), Rucaparib 15 µM and a combination therapy of IB-DNQ 0.1 µM and 
Rucaparib 15 µM. A previous dose response study by Huang et. al. found synergistic 
lethality between 15 µM Rucaparib and another NQO1 bio activable drug β-lapachone 
[20]. Rucaparib is chosen in this study since clinical grade formulation was available. 
DMSO was used as the negative control. Approximately 10 million cells were used to 
extract the proteins by denaturing with 8M urea, followed by LysC/Trypsin Gold 
(Promega) digestion. The endoprotease LysC is more stable than trypsin and is used before 
trypsin digestion under harsh, solubilizing conditions such as 8M urea. 45 µg of sample 
was used for global analysis and 3 milligrams for phosphopeptide enrichment using TiO2 
chromatography. The peptides from different treatment conditions and replicates are 
multiplexed and labelled with different Tandem Mass Tag (TMT) labels from Thermo 
Fisher. The TMT labels are isobaric having exactly the same mass but with different 
isotopes of Nitrogen (15N) and Carbon (13C). The high resolution Thermo-Orbitrap Fusion 
Lumos mass spectrometer can differentiate between the very small mass difference of the 
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isotopes of N and C. Each tag has a cleavable mass reporter which is unique and reacts 
with primary amines (peptide N terminus and Lysine residues). After labelling was 
quenched, the samples were mixed together and subjected to high pH basic fractionation 
in Thermo-Orbitrap Fusion Lumos instrument using MS3 acquisition. In MS2 stage, 
Collision Induced Dissociation (CID) is performed using helium to generate b and y 
fragment ions from breakage of peptide bonds. The b ions extend from the N-terminus and 
y ions extend from the C-terminus of the peptides. A population of those ions are selected 
by the Orbitrap for higher-energy collisional dissociation (HCD) fragmentation in MS3 
step. This breaks off the TMT reporter ion which is picked up by the detector (Figure 3). 
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Figure 3: Workflow of proteomic analysis of MDA-MB-231 cells 
 
Analysis of Raw Data 
The raw data was analyzed in Proteome Discoverer [32] for both global and 
phosphoproteomic datasets. 4383 unique proteins and 22872 phosphorylation sites were 
quantified in NQO1 positive cells and 3181 unique proteins and 8530 phosphorylation sites 
were quantified in NQO1 negative cells (Figure 4). 
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Figure 4: Number of identified proteins (blue) and phosphorylated sites (pink) in MDA-
MB-231 cells 
 
Gene Ontology (GO) Analysis 
GO summarizes the long lists of proteins into biologically meaningful information. A T-
test was performed on proteins differentially expressed between two experimental groups. 
The p-value adjustment was calculated to avoid false positives using either Bonferroni 
correction for small scale experiments or Benjamini Hochberg procedure for large scale 
experiments. The upregulated proteins with fold change ratio > 1 and down regulated 
proteins with fold change ratio < 1 are analyzed separately. The peptide level output from 
Proteome Discoverer is exported in excel format and processed in R. The UniProt protein 
accession numbers are converted to gene symbols using the mapIds function from 











NQO1 + NQO1 -
Proteins Phosphorylated sites
n = 3 n = 3
11 
library('org.Hs.eg.db')   
protein_id<- rawdata$protein_id 
id_gene<-mapIds(org.Hs.eg.db, protein_id, 'SYMBOL', 
'UNIPROT', multiVals="first") 
id_entrez<-mapIds(org.Hs.eg.db, protein_id, 'ENTREZID', 
'UNIPROT', multiVals="first") 
id_ensembl <- mapIds(org.Hs.eg.db, protein_id, 'ENSEMBL', 
'UNIPROT', multiVals = "first") 
Picture 2: R Code 
 
The rawdata was filtered by p value < 0.05 (Picture 3). 
Rucaparib <- data[, c(1,23,24,25,2:5,11,17)] 
Rucaparib_pvalue_sorted <- Rucaparib %>% filter(ratio.p_   
Rucaparib < 0.05) 
Picture 3: R code 
 
The enrichment analysis was performed using the ClusterProfiler package in R [34]. 
ClusterProfiler is an enrichment tool for statistical analysis and visualization for functional 
and comparative study. It supports three species, including H. sapiens, M. musculus and S. 
cerevisiae. Large scale protein expression analysis from mass spectrometry-based 
experiments yields many significant proteins. To understand their biological relationships 
Gene Ontology (GO) enrichment analysis was performed with the enrichGO function [35] 
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from ClusterProfiler (Picture 4). The enriched GO terms are visualized in the form of 
barplot using the R base function barplot. The bars are colored based on the adjusted p-
value calculated. 
 
Rucaparib_up1 <- Rucaparib %>% filter(ratio.p_Rucaparib < 
0.05 & abs(ratio_Rucaparib) > 1.0) 
up_Ruca_BP <- enrichGO(Rucaparib_up1 [,7], OrgDb = 
org.Hs.eg.db, 
keyType = "SYMBOL",ont="BP",  pAdjustMethod = "BH", 
pvalueCutoff=1, qvalueCutoff=1) 
Rucaparib_down1 <- Rucaparib %>% filter(ratio.p_Rucaparib 
< 0.05 & abs(ratio_Rucaparib) < 1.0) 
down_Ruca_BP <- enrichGO(Rucaparib_down1 [,7], OrgDb = 
org.Hs.eg.db, keyType = "SYMBOL",ont="BP", 
pvalueCutoff=1, qvalueCutoff=1) 
Picture 4: R Code 
 
Gene Concept Network 
While the barplots displays only the enriched terms, to view the genes associated with those 
terms the function cnetplot [36] from the package enrichplot is used [37]. Some genes may 
be associated with more than one biological pathway, which is difficult to visualize on a 
barplot. The network plot shows such linkages (Picture 5). 
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enrichplot::cnetplot(up_Ruca2) + ggtitle("NQO1+ Network 
plot of enriched terms-Rucaparib") + theme(plot.title = 
element_text(hjust = 0.5, size=20,face="bold")) 
Picture 5: R Code 
 
Gene Set Enrichment Analysis (GSEA) 
The GSEA doesn’t require cutoffs and therefore is threshold free and is more powerful 
than GO. The use of cutoffs introduces bias in the hypergeometric tests. The whole list of 
genes/proteins detected in the phosphoproteomics experiment was used. The goal was to 
determine whether the members of the gene/protein set were randomly distributed 
throughout a ranked protein list or if they were located at the top or bottom of the ranked 
list. The list of proteins was sorted based on T statistic like p value < 0.05 and the 
enrichment score (ES) is calculated using the T statistic. The ES for a set of proteins is the 
maximum value reached and that may be positive or negative. Thereafter permutations of 
the samples were performed to recalculate random ES scores. The ES was normalized 
(NES), and adjusted p value was estimated based on randomized ES (Picture 6). 
 
Picture 6: Normalized enrichment scores 
 
Here the GSEA Java desktop application from the Broad Institute was used to summarize 
the long list of proteins into biological pathways [38]. Two types of input files are required 
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for GSEA analysis; an expression dataset in gct format and phenotype annotation file in 
cls format. The cls file is required only for gct 1.2 version. The hallmark gene sets from 
MSigDB (Molecular Signatures Database) in gmt format was used for analysis [39]. The 
hallmark gene sets were generated by computational methods and summarize well defined 
biological states and processes. These gene sets reduce noise and redundancy in GSEA 
analysis. The first line in a gct 1.2 file format is always #1.2. The second line contains two 
numbers representing the number of rows and number of columns in the data matrix 
(Figure 5). Since the GSEA analysis is gene centric, gene ID’s in the form of HGNC 
symbols are used. Alternatively, the gct file can be generated using Morpheus 
(https://software.broadinstitute.org/morpheus/) by uploading the metadata in excel format 
[40]. Upload the excel file with HGNC gene symbols and log2 fold change values, change 
row and column annotations from View → Options → Annotations. Since gene centric 
pathway analysis requires single entries of genes, Morpheus can collapse the dataset to 
unique gene symbols from Tools → Collapse → select method to median → Collapse rows 
→ by id. A new tab will be created with a gene centric heatmap which can be downloaded 
in gct 1.2 format. 
 
 
Figure 5: gct 1.2 file format 
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The cls file format contains phenotype labels of each sample in the dataset, and values are 
separated by tab or space. The first line consists of three numbers; the number of samples, 
number of classes of samples and the third number is always 1. The second line begins 
with a pound sign (#) and contains the class names (e.g. wild type vs. mutant; drug vs. 
control). The third line contains class labels present in the dataset (Figure 6). 
 
Figure 6: cls file format 
 
The gct and cls files are loaded in GSEA using ‘Load data’, ‘Run GSEA’ option lets the 
user choose the expression dataset (gct file), Gene set database (Hallmark gene sets in gmt 
format from dropdown menu) and Phenotype labels (cls file). Number of permutations 
(1000), no collapse of gene symbols, Permutation type (gene sets), Chip platform to be 
kept blank. Rename the analysis and save results in desired folder keeping other options as 
default. The permutations mean repeating the analysis 1000 times and creating a 
distribution of ES scores. The significant ES scores are used to calculate p-values. The 
‘Run’ option will run the analysis and generate GSEA reports on the left panel.  
 
Computational Method for Kinase Enrichment Analysis 
Various computational tools are available to decipher the kinases associated with the 
identified phosphorylation sites. But all these tools have certain drawbacks with respect to 
the organisms they support and the number of kinases they can predict. Majority of such 
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tools require complete fasta sequences of proteins rather than individual phosphorylation 
sites detected from MS based phosphoproteomic experiments (Table 1). 
 
Table 1: Computational tools available for phosphorylation site and kinase prediction 
 
Kinase Set Enrichment Analysis or KSEA is an approach to infer the kinase activity from 
phosphoproteomics dataset based on individual phosphorylation sites. KSEA is published 
as a freely available Python code (Python version 2.7.x) [41] and also as an R shiny app 
[41]. Both of these resources infer the kinase activity by utilizing prior knowledge of 
kinase-substrate relationships from curated databases or computational prediction tools. 
Here the R shiny app version of the tool called KSEAapp was used, available as an R 
package on CRAN: CRAN.R-project.org/package¼KSEAapp/. Currently the KSEA tool 
only supports human kinases but other organisms can also be analyzed by extracting the 
species-specific kinase-substrate entries from the dataset available on PhosphoSitePlus. 
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KSEA Algorithm Overview 
The KSEA algorithm works on the phosphoproteomics dataset with test and control 
samples. The algorithm takes an input file in csv format consisting of a list of peptides, 
corresponding protein and gene names, phosphosites and associated fold change (FC) and 
p values. The gene names, phosphosites and FC (not log transformed) values are necessary 
for the calculations. The protein, peptide and p values are optional, but the headers must 
be present in the input file with the rest of the column as ‘NULL’ but not left blank. KSEA 
uses kinase substrate relationships from both PhosphoSitePlus [42] and NetworkIn [43], 
and users have a choice of selecting kinase-substrate relationship from PhosphoSitePlus 
alone or both PhosphoSitePlus and NetworkIn to improve coverage or get more kinases. 
The p-value cutoff and substrate count cutoff are required for the bar plot and was set at 
0.05 and 2, respectively. The value of 2 for substrate count cutoff means any kinase with a 
minimum of 2 substrates will be included in the barplot. The algorithm scores each kinase 
based on the relative hyperphosphorylation and dephosphorylation of its substrates, as 
identified from the phosphosite specific databases such as PhosphoSitePlus and 
NetworkIn. The positive and negative values represent an increase or decrease in kinase 
activity in response to drug treatment relative to control. The kinase is scored based on the 
formula: 
 
Picture 7: Kinase score formula 
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Where ?̅? denotes the mean log2(FC) of known phosphosite substrates of the given kinase, 
?̅? represents the mean log2(FC) of all phosphosites in the dataset, m denotes the total 
number of phosphosite substrates identified from the experiment that annotate to the 
specified kinase, and δ denotes the standard deviation of the log2(FC) across all 
phosphosites in the dataset. This formula is based on a z-score transformation, and the 
resulting scores (denoted as ‘z-score’ in the KSEA App outputs) are assumed to be 
normally distributed. Subsequently, the p-value is determined by assessing the one-tailed 
probability of having a more extreme score than the one measured, followed by a 
Benjamini-Hochberg FDR correction for multiple hypothesis testing [44]. The Benjamini-
Hochberg procedure is a statistical tool to control false discovery rate (FDR) in multiple 
hypotheses testing and control false positives.  
 
Input File Preparation 
The phosphoproteomic dataset for NQO1 positive cells was prepared using R. The columns 
‘Master protein accessions’, ‘Sequence’, ‘Modifications in master proteins’, ‘Abundance 
ratio’ and ‘Abundance ratio p-value’ for different treatment conditions were chosen for 
KSEA analysis. The column ‘Modifications in master proteins’ was edited in excel itself 
to remove all texts except the modified phosphosites, multiple phosphosites were separated 
by a semicolon without any spaces. Since KSEA only takes HGNC gene symbols, the 
UniProt identifications from the phosphoproteome dataset were converted to HGNC gene 





protein_id <- rawdata$protein_id 
id_gene<-mapIds(org.Hs.eg.db, protein_id, 'SYMBOL', 
'UNIPROT', multiVals="first") 
Rucaparib <- data[, c(1,21,2,4,16,6)] 
Rucaparib_pvalue_sorted <- Rucaparib %>% 
filter(ratio.p_Rucaparib < 0.05 & 
!is.na(ratio.p_Rucaparib) & !is.na(id_gene) & 
!is.na(`Modifications in Master Proteins`)) 
Picture 8: R Code 
 
Finally, the columns are named as per the requirements of the KSEAapp algorithm (Picture 
9). 
colnames(Rucaparib_pvalue_sorted)<-c("Protein", "Gene", 
"Peptide","Residue.Both", "p", "FC") 
Picture 9: R Code 
 
Sequence Motif Analysis 
The specificity of protein kinases is associated with the consensus sequence surrounding 
the phosphorylated serine, threonine and tyrosine residues. The motif analysis is performed 
with the ggseqlogo R Bioconductor package [45]. ggseqlogo takes two types of input: a 
character vector of sequences or position frequency matrix (PFM) or Position-Specific 
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Scoring Matrix (PSSM), where the rows are amino acids and the columns are the positions 
of those amino acids. The peptide sequences from kinase-substrate relationships from the 
KSEA analysis was used as input (Picture 10).  
ggseqlogo(PLK1_data, seq_type='aa') 
Picture 10: R Code 
 
The ggseqlogo algorithm builds a matrix of all the peptide sequences with amino acids on 
the rows and the positions correspond to the alignment columns. The algorithm calculates 
the probability of observing an amino acid at that position. The dash means the amino acid 
is not present in the peptide sequence (Table 2, Table 3). 
 
 
Table 2: Matrix of PLK1 peptide sequences; the rows represent peptide sequences and 




Table 3: Position-Specific Scoring Matrix (PSSM) of PLK1 peptide sequences 
 
A sequence logo is a graphical representation of the aligned sequences, where the size of 
each residue is proportional to its frequency at that position and total height of all the 
residues in the position is proportional to the conservation of the position. The height of 
the amino acids is measured by the entropy and is depicted as bit score shown on the Y 
axis and is calculated using the formula: (Picture 11) 
 
Picture 11: Sequence motif formula 
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The frequency of an amino acid at a position is calculated and multiplied by log2 of the 
frequency of that amino acid at that position. This value is subtracted from the log220 in 
the case of protein sequences, as there are 20 amino acids. H is Shannon entropy. R is 4.32 
bits in case of protein sequences, which is log2(20). This strategy can be used to discover 
motifs from sets of phosphorylation sites detected in phosphoproteomic experiments.  
 
Visualization of Kinome Data 
To visualize the kinome data identified by Kinase Enrichment Analysis, an interactive R 
shiny web application called CORAL was used [46]. CORAL allows the visualization of 
both qualitative and quantitative data in three modes: the traditional kinome tree, based on 
Cell Signaling Technology, the radial network with the nodes representing kinase, groups, 
families and subfamilies, and dynamic force networks. The node color, node size and 
branch color can be customized according to user requirements. The quantitative kinase 
enrichment data with corresponding log2-fold change values is used as input to highlight 
differentially expressed kinases or highlight targets of kinase inhibitors. The Shiny web 
application is available at http://phanstiel-lab.med.unc.edu/CORAL/. In the Plot tab, color 
scheme is selected as Quantitative for all the parameters and the kinase HGNC symbols 
and corresponding log2-fold change values from KSEA analysis are entered in separate 
rows. The plots are automatically populated based on the input data and nodes colored 





Protein-Protein Interaction Analysis 
The cellular signaling process is dependent on interaction between the proteins which are 
highly specific physical interactions. These interactions are controlled by electromagnetic 
and electrostatic forces, hydrogen bonding and hydrophobic effect. Understanding PPIs is 
important for comprehending cellular process and disease microenvironment. StringDB 
was used for protein interaction analysis and the corresponding fold change values are 
overlaid on the network with Cytoscape for visual representation of the up and 
downregulated proteins under different treatment conditions. The UniProt accessions were 
imported under the ‘STRING: protein query’ as data source to create the PPI network. The 
nodes are colored according to the fold change values by importing the excel data table 
directly. To understand the systems level interaction of the identified proteins with other 
proteins in the network, additional interactions from PPI databases can be imported while 
creating the String network. 
 
Kinase Substrate Interaction Network 
The kinase and phosphosite correlation obtained from the KSEA analysis was used to infer 
the kinase and substrate regulatory relationship and construct a kinase-substrate interaction 
network in breast cancer. The kinase-substrate link output file from KSEA can be directly 
used as input to create the network in Cytoscape [47]. Cytoscape is a versatile program to 
create a customized network from any type of interaction data and provides a range of 
applications as plugins for layering. The kinase gene was set as the source node and the 
substrate gene set as target node, substrate modification can be set as target node attribute 
for layering to create more informative networks, log2FC was selected as the edge attribute. 
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The resulting network was converted into a String network from Apps → String → 
Stringify network with a confidence score cutoff of 0.70. Note that UniProt identifications 
provide better results with String database [48] and therefore, kinase gene names must be 
converted to UniProt accession numbers. The kinase information from public database is 
layered by importing kinase-substrate network from PubMed, File → Import Network from 
Public Databases → Data Source (String: PubMed Query) → Species (Homo sapiens) → 
keyword (kinase) → confidence score cutoff of 1.00 → Maximum number of proteins = 
100. The networks are merged to create an intersection network. Cytoscape also allows 
















RESULTS AND DISCUSSION 
Global and Phosphoproteome Analysis of NQO1 Positive MDA-MB-231 Cells 
NQO1 was detected in the NQO1 positive samples but it was not detected in the NQO1 
negative samples, however there was no statistically significant change in NQO1 
abundance in NQO1 positive samples. The hierarchical clustering of proteins differentially 
expressed relative to DMSO in four samples of MDA-MB-231 cells treated with 0.4 µM 
IB-DNQ, 0.1 µM IB-DNQ, 15 µM Rucaparib and a combination therapy of 0.1 µM IB-
DNQ and 15 µM Rucaparib shows separation of protein expression in different clusters. 
Protein intensity is presented in logarithmic scale with lower intensity color coded in red 
and high intensity colored in green. The rows represent individual proteins and the columns 
represent samples. A large number of proteins are significantly changed in combination 
therapy with both upregulation and downregulation and a few changes in 0.4 µM IB-DNQ 
compared to Rucaparib 15 µM and low dose 0.1 µM IB-DNQ. It is clearly visible from the 
heatmap that proteins that are upregulated in combination therapy (green) show different 
expression patterns in IB-DNQ 0.4 µM (colored red) indicating that the combination 
therapy causes more perturbations in protein expression than IB-DNQ alone. Also, very 
few changes are observed in single agent Rucaparib treatment compared to all other drug 
concentrations (Figure 7). 
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Figure 7: Hierarchical clustering of differentially expressed protein from 
phosphoproteome experiment in NQO1 positive cells 
 
The volcano plots allow for quick identification of genes with large fold changes that are 
also statistically significant in terms of p value. Each dot represents a protein and the 
outliers represent most highly differentially expressed proteins. TNBC cells reveals clear 
differences in global protein levels between NQO1 positive (+) and NQO1 negative (-) 
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cells. Very few changes are observed in NQO1 negative cells (as compared to the DMSO 
control), while in NQO1 positive cells, only one protein is found to be significant in single 
agent Rucaparib 15 µM treated cells (marked in red). Significant changes are observed in 
cells treated with the combination therapy (0.1 µM IB-DNQ and 15 µM Rucaparib) and 
0.4 µM IB-DNQ treatment (Figure 8). As IB-DNQ is bioactivated by NQO1, the status of 
NQO1 is responsible for the changes observed in NQO1 positive and NQO1 negative cells. 
Since larger changes are observed in NQO1 positive cells in response to IB-DNQ alone 
and in combination with Rucaparib, our analysis here is focused on the changes relative to 
DMSO in NQO1 positive cells only. In the case of peptide level changes in the 
phosphoproteome analysis with different treatments of IB-DNQ and Rucaparib, few 
changes are observed in single agent 15 µM Rucaparib. In the case of 0.4 µM IB-DNQ and 
combination therapy drugs, significant changes are observed with more pronounced effects 
in the latter. Downregulation of POLR2A C- terminal domain (CTD) and IWS1, a histone 
chaperone protein involved in transcription elongation indicate suppression of transcription 
machinery and upregulation of H2AX and XPC phosphorylation indicates DNA damage 
due to generation of free radicals by NQO1 mediated IB-DNQ bioactivation (Figure 9). 
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Figure 8: Volcano Plots showing comparison of global protein levels in NQO1 positive 
and NQO1 negative cells 
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Figure 9: Volcano Plots showing comparison of phosphopeptide level changes in NQO1 
positive and NQO1 negative cells 
 
Gene Ontology Analysis of Phosphoproteome Dataset 
GO term analysis reveals enrichment for mRNA processing, ATP dependent chromatin 




Figure 10: Upregulated Gene Ontology (GO) terms for Biological Process in NQO1 
positive cells treated with combination drug therapy 
 
 
Figure 11: Upregulated Gene Ontology (GO) terms for Molecular Function in NQO1 
positive cells treated with combination drug therapy 
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Figure 12: Upregulated Gene Ontology (GO) terms for Cellular Component in NQO1 
positive cells treated with combination drug therapy 
 
The barplots shown above only display the significantly enriched terms. The gene concept 
network shows the genes or proteins that are associated with those terms. Sometimes genes 
may be associated with multiple biological pathway categories and to view this complex 
association, a network plot is useful. For combination drug treated cells, we see 
downregulation of POLR2A, IWS1, XRCC1, TP53BP1, and KAT7 indicating suppression 
of DNA damage response proteins. XRCC1 and TP53BP1 are involved in DNA double 
stranded break repair pathways while KAT7 (histone acetyltransferase KAT7) is 
responsible for ATR phosphorylation and histone acetylation to recruit XPC at the DNA 
damaged sites in nucleotide excision repair (NER) pathway. IWS1 is a histone chaperone 
protein involved in transcription elongation, and POLR2A indicates downregulation of 
transcription machinery in response to drug treatment with a combination of IB-DNQ 0.1 
µM and Rucaparib 15 µM (Figure 13). Also, upregulation of proteins involved in DNA 
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damage, unfolded protein response (UPR) and inhibition of transcription machinery agrees 
with the hypotheses that the combination of NQO1 bio-activable drug and PARP inhibitor 
is more effective in killing cancer cells. For example, H2AX is a variant of histone H2A 
which plays a central role in transcriptional regulation by checkpoint mediated cell cycle 
arrest in response to DSBs. It is phosphorylated at Ser-140 to form gamma-H2AX or 
H2AX-139ph and is an indication of DNA damage [49]. HNRNPU inhibits transcription 
elongation by inhibiting the C-terminal domain (CTD) of POLR2A, and PSMD4 is 
responsible for maintaining protein homeostasis by removing misfolded or damaged 
proteins. PML and SP100 plays a role in positive regulation of p53/TP53 and double 









Figure 13: Gene Concept Network of downregulated proteins POLR2A, IWS1, XRCC1, 
TP53BP1, and KAT7 in Biological Process GO terms in combination therapy. The nodes 




Figure 14: Gene Concept Network of upregulated proteins H2AX, HNRNPU, PSMD4, 
SP100 and PML in Biological Process GO terms in combination therapy. The nodes are 
the GO terms 
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Previous studies [50] have described the role of SWI-SNF complex in tumor suppression 
by transcriptional regulation and DNA damage response. Mutations and changes in overall 
expression of SWI-SNF complex subunits is associated with poor prognosis in many 
cancer types including breast cancers [51][52]. Upregulation of INO80B, HDAC2, 
PBRM1, RSF1, SMARCC2, CHD3, ARID1A, SLC9A1 in combination therapy indicates 
transcription suppression and DNA damage response (Figure 19). Mutations in PBRM1, 




Figure 15: Gene Concept Network of upregulated proteins belonging to SWI-SNF family 
in combination therapy. The nodes are the GO terms 
 
Upregulation of DNA damage sensor proteins like MMS19, FOXK1, ATM, histone 
deacetylation (CHD4) and transcription repression (GATAD2B) was observed in IB-DNQ 
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0.4 µM treated cells. MMS19 is associated with NER and HR mediated DNA repair, PNKP 
is associated with both non-homologous end joining (NHEJ) and base excision repair 
(BER) pathways, and ATM activates checkpoint signaling upon encountering DSBs and 
phosphorylates Ser-139 of H2AX (Figure 16,17,18). 
 
 
Figure 16: Gene Concept Network of upregulated proteins (PNKP, ATM, FOXK1) in 





Figure 17: Gene Concept Network of upregulated proteins (CHD4, GATAD2B) in 
Molecular Function GO terms in IB-DNQ 0.4 µM. The nodes are the GO terms 
 
Figure 18: Gene Concept Network of upregulated proteins (MMS19, ATM, GATAD2B) in 
Cellular Component GO terms in IB-DNQ 0.4 µM. The nodes are the GO terms 
38 
Downregulation of most proteins related to mRNA regulation, MTORC1 pathway (TSC2, 
LARP), focal adhesion (CTTN) and podosome (TJP1, ASAP1, SVIL) is seen in 0.4 µM 
IB-DNQ. All the proteins belonging to the GTPase regulation node are associated with Ras 
signaling pathway such as RASAL2 inactivates Ras-cyclic AMP pathway. These proteins 
are also annotated in DisGeNET for their association with different forms of cancer (Figure 
19,20,21). Podosomes are actin enriched protrusions that are responsible for the 
invasiveness or metastases of many cancer types including breast cancer and play a role in 
cell migration. They are formed in cells that need to cross tissue boundaries like monocytes, 
dendritic cells or macrophages. Cellular tyrosine kinases like Src and Csk play major roles 
in podosome regulation [53]. In cancer cells they are called invadopodia, which cause 
degradation of extracellular matrix by protease activity and promote crossing of tissue 
barrier by cancer cells. MDA-MB-231 breast carcinoma cells are well studied for 





Figure 19: Gene Concept Network of downregulated proteins in Biological Pathways GO 
terms in IB-DNQ 0.4 µM. The nodes are the GO terms 
 
Figure 20: Gene Concept Network of downregulated proteins (TSC2, LARP1, CTTN) in 
Molecular Function GO terms in IB-DNQ 0.4 µM. The nodes are the GO terms 
40 
 
Figure 21: Gene Concept Network of downregulated proteins (TJP1, ASAP1, SVIL) in 
Cellular Component GO terms in IB-DNQ 0.4 µM. The nodes are the GO terms 
 
ABL1 a tyrosine protein kinase, ATAD2 involved in proliferation and cell cycle 
progression in breast cancer cells, and KDM2B a histone demethylase was found to be 
downregulated in Rucaparib 15 µM treated cells (Figure 22). ABL1 is involved in DNA 
damage response and some of its substrates are mediators of DNA repair. 
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Figure 22: Gene Concept Network of downregulated proteins (ABL1, ATAD2, KDM2B) in 
Biological Pathways GO terms in Rucaparib 15 µM. The nodes are the GO terms 
 
However, GO analysis have certain limitations towards extensively studied proteins and 
pathways. Certain areas of biology are more well studied and thoroughly annotated than 
others. This introduces certain bias into the statistical analysis. Also, GO is based on 
manual curation or computational approaches and the existing annotation databases are 
largely incomplete. If a protein is detected but there is no reference of it in the published 
literature, the algorithm will ignore that protein. The interpretation of the experiments will 
also change over time as more and more data become available and annotations are 




Gene Set Enrichment Analysis (GSEA) 
While GO analysis uses ranked list of proteins, GSEA is threshold free and considers the 
whole list of proteins detected in the experiment. The hypothesis behind this method is that 
small changes in sets of functionally related genes or proteins may also be important in 
addition to genes having large expression changes. The hallmark gene set of cancer gene 
pathways from MSigDB is used for GSEA analysis. Upon comparing the combination 
therapy treated cells against all other drug treatment conditions, genes related to P53 
pathway, IL2 STAT5 signaling, WNT signaling, apoptosis, G2M checkpoint, JAK STAT 
pathway, glycolysis, KRAS signaling and oxidative phosphorylation are found to be 
positively correlated in combination therapy. Whereas in the rest of the drug treated cells 
perturbations in MTORC1, MYC, E2F targets, DNA repair pathway genes, interferon 
gamma response and unfolded protein response pathways are observed (Figure 23). These 
changes were not observed in GO enrichment analysis due to the bias introduced by p value 




Figure 23: Barplot of GSEA analysis in combination therapy vs rest of the drugs 
(Rucaparib 15 µM, IB-DNQ 0.1 µM, IB-DNQ 0.4 µM) 
 




















































The E2F, P53 pathway genes, G2M checkpoint genes are expressed in cells treated with 
combination therapy drugs, whereas genes belonging to glycolysis pathway, epithelial to 
mesenchymal transition (EMT), PI3K/AKT/mTOR signaling and MTORC1 signaling are 
expressed in single agent Rucaparib treatment (Figure 24). The enrichment plots of the 
pathways clearly show the correlation between the two conditions. As the analysis walks 
down the hallmark cancer gene list, it scores the genes present in the experimental gene 
set. The green peaks represent enrichment score, which is the maximum deviation from 
zero. Gene sets with a distinct peak at the beginning or end of the gene set is significant. 
The vertical bars in the middle represent the position of each gene towards the top or bottom 
of the ranked list of proteins. The bottom portion of the plot shows the value of ranking 
metric. A positive value indicates correlation with the first phenotype and upright peak and 




Figure 24: Barplot of GSEA analysis in combination therapy vs 15 µM Rucaparib 
 
 















































Figure 25: GSEA enrichment plots of the upregulated pathways between combination 
therapy and 15 µM Rucaparib. These pathways are positively correlated with combination 
therapy as shown by the peak at the beginning of the ranked gene list 
 
In Figure 25, a comparison between drug conditions show that the genes for E2F targets, 
P53 pathway, G2M checkpoint and apoptosis are more enriched in the combination therapy 
treated cells than single agent Rucaparib as shown by positive correlation in the enrichment  
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plots, while genes for glycolysis, EMT, PI3K and MTORC1 signaling are more enriched 
in Rucaparib treatment than combination therapy (Figure 24). 
 
 
Figure 26: Barplot of GSEA analysis in combination therapy vs 0.4 µM IB-DNQ 
 
Figures 26, 27 show the correlation of apoptosis and TGF beta signaling proteins in 
combination therapy compared to 0.4 µM IB-DNQ treatment, whereas proteins belonging 
to G2M checkpoint and E2F targets are enriched in both the treatment conditions. 















































Figure 27: GSEA enrichment plots of the downregulated pathways between combination 
therapy and 0.4 µM IB-DNQ 
 
Protein-Protein Interaction Network Analysis 
The PPI analysis from StringDB shows 342 protein nodes and 1783 edges. To reduce the 
complexity of the network, the MCODE plugin (Molecular Complex Detection) in 
Cytoscape was used. MCODE can find clusters of highly interconnected regions in a 
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protein interaction network that may represent molecular complexes [55] (Figure 28). The 
network is broken down into three clusters of DNA damage related proteins, DNA repair 
proteins and proteins related to transcription machinery (Figure 29). The high 
interconnectivity between the proteins in a cluster represents a strong interaction amongst 
the proteins in biological processes. The darker color of the nodes represents higher 
expression based on fold change values. For example, HNRNPU blocks transcription of 
POLR2A transcription elongation by blocking CTD phosphorylation, H2AFX and XPC is 





Figure 28: Protein-protein interaction network for combination therapy showing densely 
interconnected proteins (created using Cytoscape String app). The nodes are colored 
based on fold change values 
51 
 
Figure 29: To reduce complexity the dense network is broken down into clusters of highly 
interconnected proteins from combination therapy. The clusters DNA damage, DNA repair 





Figure 30: Protein-protein interaction network for 0.4 µM IB-DNQ (created using 
Cytoscape String app). The nodes are colored based on fold change values. Compared to 




Figure 31: Protein-protein interaction network for 15 µM Rucaparib (created using 
Cytoscape String app). The nodes are colored based on fold change values. Very few 
interactions are observed between the proteins in the network 
 
In contrast the PPI networks of 0.4 µM IB-DNQ and 15 µM Rucaparib show fewer 
interacting proteins with network enrichment for posttranscriptional regulation of gene 
expression, cell cycle process and spliceosome components (Figure 30,31). These findings 
suggest a possible structure for PPI networks with dense interconnected and self-regulated 
central core which has high participation in the controllability of the full network as we 
saw in combination therapy. The peripheral nodes are less regulated and do not play 
important role in the propagation of signals. However, each primary PPI database (MINT, 
DIP, IntAct, HPRD, BioGRID, BIND) show little overlap amongst them [56]. To increase 






The phosphoproteomic study presents a rich source of biological knowledge and requires 
novel data analysis and modeling paradigms. The next challenge is to delineate detected 
phosphorylation sites to their effector kinases. The KSEA provides a computational 
approach using literature mining to decipher the kinases responsible for the 
phosphorylation events. The phosphosites from the experimental dataset were used as 
input. After the analysis is performed, three output files are produced, KSEA kinase scores, 
Kinase-Substrate links and KSEA barplot. The barplot summarizes the KSEA results and 
only includes kinases with a substrate count cutoff of 2. The kinases that do not pass this 
cutoff will be excluded from the barplot and available in the KSEA kinase scores, Kinase-
Substrate relationships table outputs. The p-value cutoff of 0.05 that was set before the 
analysis decides which kinases will be marked statistically significant. Phosphosites with 
decreased phosphorylation in the drug treated group will have a fold change ratio of less 
than 1 (where the fold change ratio was determined by Drug/Control), leading to log2FC 
value in negative and will be marked in blue. The KSEA kinase scores table provides a list 
of all the kinases including those that are not included in the barplot and that have at least 
one identified substrate in the input dataset. This may be useful for generating custom 
graphs for in-depth analysis. The Kinase-Substrate links table provides a list of all K-S 
relationships identified from the experimental phosphoproteome dataset and shows every 
substrate identified from the dataset that contributed to the kinase’s score. 
For kinases such as CDK1, CLK1 and CDK2 whose substrates that are 
dephosphorylated with drug, its normalized score will be negative in value (Figure 32). 
So, these kinases are deemed downregulated with combination drug treatment because its 
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signaling output is decreased in that group relative to control and will be marked in blue. 
Similarly, phosphosites with increased phosphorylation in the drug treated group will have 
a fold change ratio of greater than 1, leading to log2FC value in positive and will be marked 
in red. Kinases such as NEK2, IKBKB, PRKCI, MAP2K5, CHUK, RPS6KA2, ATM, 
TGFBR2, PDK1, CHEK1, PAK2, PLK1, ROCK1, AURKC are upregulated upon 
combination drug treatment. Kinases with non-significant scores will be colored in black. 
IKBKB is a serine kinase that plays an essential role in the NF-kappa-B signaling pathway, 
which is activated by multiple stimuli such as DNA damage or other cellular stresses. The 
serine/threonine protein kinase ATM activates checkpoint signaling upon double strand 
breaks (DSBs) and apoptosis by acting as a DNA damage sensor and phosphorylates Ser-
139 of histone variant H2AX at double strand breaks (DSBs), to regulate DNA damage 




Figure 32: KSEA barplot for NQO1 positive combination treatment (15 μM Rucaparib and 
0.1 μM IB-DNQ). The upregulated and downregulated kinases according to p-value are 




The Polo like kinase PLK1 is responsible for DNA damage response and G2 DNA damage 
checkpoint recovery by inactivating the ATR/Chk1 pathway through inhibition of 53BP1 
and Chk1 activator Claspin. Phosphorylation at Thr-210 is responsible for the catalytic 
activity of PLK1. Precise regulation of PLK1 activity is essential for cell cycle regulation 
but the mechanism is not fully understood. A study by Weizhe Li et. al showed that PLK1 
is controlled by a balanced methylation and phosphorylation switch with the methylation 
occurring at Lys-209 [57]. Additional studies also suggest that phosphorylation or 
autophosphorylation of Ser-137 may enhance activity of PLK1 during DNA damage 
recovery although it is not essential for PLK1 activation  [38][59]. A number of studies 
have revealed that PLK1 is highly expressed in most human cancers, and its overexpression 
is associated with poor prognosis in cancer patients [60][61]. In breast cancer, it is 
associated with aggressive characteristics, such as vascular invasion, markers of 
proliferative activity and lack of detectable estrogen receptor [62]. There was also a close 
association of elevated PLK1 with triple negative tumors, considered to be poor prognosis 
breast cancers that generally harbor TP53 mutation. It is found that patients with TP53 
mutation and detectable PLK1 show reduced survival and are more likely to have a triple 
negative genotype [63]. P53-null cells are unable to down-regulate PLK1 levels in response 
to clinically-relevant genotoxic drugs. Cancer cells sometimes show increased dependence 
on normal cellular functions of certain genes which are not classical oncogenes, such 
as PLK1. This phenomenon is called non-oncogene addiction. In a recent genome-scale 
shRNA (short hairpin RNA) screen of the human breast cancer,  PLK1 was a hit in several 
TNBC cell lines, indicating its importance for growth and survival of these breast cancer 
cells [64]. PLK1 has drawn a lot of attention because its overexpression is tightly associated 
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with neoplastic transformation of human cells.  PLK1 overexpression is thought to promote 
tumorigenesis by overriding cellular checkpoints and inducing genetic instability. 
Reversing oncogene addictions in cancer cells has been shown to induce apoptotic cell 
death. Therefore, increased sensitivity of cancer cells to PLK1 interrogation may likely 
stem from their altered signaling pathways and biochemical steps in PLK1-addicted cancer 
cells. Some contrasting studies show a tumor-suppressive role for Plk1 in certain tumors 
[65]. 
PLK1 is a CDK1 kinase but in the KSEA analysis for combination therapy drugs it 
is in the upregulated area whereas CDK1 is downregulated upon drug treatment. This 
conflict is explained by the phosphorylation of CDK1 on Tyr-15 by WEE1. PLK1 plays a 
central role in the G2/M transition of the mitotic cell cycle by phosphorylating CCNB1, 
CDC25C, FOXM1, CENPU, PKMYT1/MYT1, PPP1R12A/MYPT1 and WEE1. It is part 
of a regulatory circuit that promotes the activation of CDK1 by phosphorylating the 
positive regulator CDC25C and inhibiting the negative regulators WEE1 and 
PKMYT1/MYT1 [66]. WEE1 acts as a negative regulator of entry into mitosis (G2 to M 
transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed 
CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on Tyr-15. 
Phosphorylation of CDK1 at Tyr-15 by WEE1 and PKMYT1 reduces kinase activity and 
is found in our combination treatment data (Table 4). WEE1 specifically phosphorylates 
and inactivates cyclin B1-complexed CDK1, reaching a maximum during S and G2 phase 
and decreases at M phase when it is hyperphosphorylated. The inability of PLK1 to inhibit 
WEE1 can be one reason for the downregulation of CDK1 [67]. 
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Kinase.Gene Substrate.Gene Substrate.Mod Source log2FC 
WEE1 CDK1 Y15 PhosphoSitePlus -0.89164 
PKMYT1 CDK1 Y15 PhosphoSitePlus -0.89164 
Table 4: CDK1 is phosphorylated on Tyr-15 by WEE1 and PKMYT1 
 
This also explains the CDK1 and CDK2 alteration following IB-DNQ treatment. IB-DNQ 
undergoes a futile redox cycling in NQO1 positive cells through a twostep process 
generating two superoxide moieties, which generate massive amounts of H2O2 that carries 
out DNA damage. The damaged DNA causes cell cycle arrest by recruiting ATM and ATR. 
The ATR is specifically recruited to single-stranded DNA breaks (SSBs) and coats the 
single-stranded DNA with replication protein A (RPA) and phosphorylates Chk1. ATM is 
recruited to double-stranded DNA breaks (DSBs) by MRN (Mre11-Rad50-Nbs1) complex 
and phosphorylates Chk2 [68]. Upon activation, Chk1 and Chk2 in turn phosphorylate 
WEE1 and antagonize the function of Cdc25 phosphatases, which leads to accumulation 
of inhibitory phosphates on Tyr-15 and Thr-14. WEE1 phosphorylates CDK1 on Tyr15, 
resulting in CDK1 inhibition and a stalled cell cycle [69]. Since CDK1 plays a regulatory 
role in homologous recombination mediated DNA repair pathway by phosphorylating 
BRCA1, its inhibition stops DSB repair in BRCA1 positive as well as BRCA mutated cells 
[70]. This causes increased hypersensitivity of cancer cells to PARP1 inhibitors like 
Rucaparib. Also, since CDK1/2 phosphorylates MRN complex, CtIP, Ku, PIN1, RPA, 
Exo1, and DNA2, its inhibition compromises single-stand DNA end resection in HR repair 
pathway [71]. The combined action of CDK1/2 inhibition by reactive oxygen species 
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(ROS) generation by IB-DNQ and PARP inhibitor Rucaparib prevented repair of DNA 
break and ultimately death of cancer cells [72] (Figure 33). 
 
 
Figure 33: Schematic of CDK downregulation upon IB-DNQ treatment 
 
Overrepresented sequence patterns among detected phosphorylation sites may correspond 
to phosphorylation motifs of kinases. This strategy is useful for detecting novel 
phosphorylation motifs of uncharacterized kinases. PLK1 (Polo-like kinase) contains PBD 
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(Polo Box Domain) that binds to substrates containing the consensus sequence S-pS/pT-
P/X (Figure 34), where pS and pT stand for phosphorylated serine and threonine 
respectively. This is similar to the consensus sequence of CDK1 phosphorylation (Figure 
35). 
 
Figure 34: PLK1 consensus motif (created with ggseqlogo R package) 
 
 
Figure 35: CDK1 consensus motif (created with ggseqlogo R package) 
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It is hypothesized that CDK1 primes a substrate for further phosphorylation and regulation 
by PLK1. In the absence of substrate, PBD binds to the kinase domain of PLK1 and inhibits 
its activity. After PBD binds to a phosphorylated substrate, it will move out of the active 
site of PLK1, which allows PLK1 to phosphorylate the substrate at a second site. This 
ensures that free kinase is held in an inactive state until it binds the correct substrate  [11]. 
So, in the absence of CDK1 or downregulation of CDK1 in combination treatment, PLK1 






Figure 36: Kinome tree showing differentially active kinases in 0.1µM IB-DNQ + 15µM 
Rucaparib combination treatment (as determined by substrate abundance) 
 
Visualization of the quantitative data from the KSEA substrate analysis on a kinome tree 
suggests more changes in overall kinome activity with most of the upregulated kinases 




Figure 37: KSEA barplot for NQO1 positive 0.4 μM IB-DNQ treatment 
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Figure 38: Kinome tree showing differentially active kinases in 0.4µM IB-DNQ (as 
determined by substrate abundance) 
 
More changes in kinase activity were observed in the combination therapy and 0.4 µM IB-
DNQ as compared to the low dose 0.1 µM IB-DNQ and single agent Rucaparib 15 µM 
treatment (Figure 37,39,41). Visualization of the quantitative data on the kinome tree 
shows decreases in kinase activity in all kinase families in Rucaparib 15 µM treatment 
while in IB-DNQ treatments both increases and decreases are observed in AGC and CK1 
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family kinases (Figure 38,40,42). This information can be useful to understand the 
interrelationships between kinases and develop therapeutic strategy targeting kinases. 
 
 





Figure 40: Kinome tree showing differentially active kinases in 0.1µM IB-DNQ (as 










Figure 42: Kinome tree showing differentially active kinases in 15µM Rucaparib single 
agent treatment (as determined by substrate abundance) 
 
Kinase Activation and Substrate Phosphorylation 
The detection of the phosphorylation sites and their dynamics under different cellular 
conditions has necessitated the reconstruction of transient kinase-substrate interaction 
networks, that are essential for mechanistic understanding of cellular behavior and 
therapeutic intervention by computational analysis of underlying data. The data from 
KSEA analysis was used for network analysis of kinase-substrate interactions. The red 
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triangles represent kinases, the green diamonds represent transcription factors, and the blue 
circles represent all other substrates. The hub proteins or proteins with high 
interconnectivity with other proteins can have large downstream signaling effects upon 
perturbation. CDK1, CDK2, MAPK3 and PRKCB are highly interconnected kinase in 
kinase interaction data from combination therapy. For example, CDK1 can trigger 
hundreds of time resolved downstream signaling events through independent 
phosphorylations (Figure 43). 
Dense interconnectivity between the kinases is observed in the kinase-substrate 
interaction network of 0.4 µM IB-DNQ (Figure 44). The substrates ate largely located 
towards the periphery of the network suggesting the kinases are interacting amongst 
themselves. In single agent Rucaparib, very few kinase-substrate interactions are visible 
(Figure 45). Based on these interaction networks, it is possible to predict the clinical 
outcomes of the drugs used in triple negative breast cancer by examining changes in 







Figure 43: Kinase-Substrate Interaction Network in Combination therapy (created with Cytoscape). Certain kinases like CDK1 are 




















Breast cancer is a leading cause of death among all other types of cancer in women 
worldwide. TNBC is the most invasive form of breast cancer and has a poorer prognosis 
than hormone receptor positive and HER2 type breast cancers. The treatment strategy 
available for TNBC is chemotherapy combined with PARP inhibitors in BRCA1 and 
BRCA2-deficient breast cancers. But despite initial success, resistance to PARP1 inhibitors 
was found in many subtypes of TNBC including off-target effects. Thus, it is important to 
find alternative treatments that can selectively target cancer cells and also improve 
sensitivity to PARP1 inhibitors.  In this study, TNBC cells overexpressing NQO1 were 
treated with NQO1 bio activable drug IB-DNQ, which produces ROS accumulating large 
amounts of H2O2 causing DNA damage. Normal cells remove the H2O2 using catalase, but 
most solid cancers including breast cancer cells have low levels of catalase and high 
expression of NQO1. This difference in NQO1: catalase ratio between normal and cancer 
cells provides an excellent therapeutic window. The increase in H2O2 levels causes PARP1 
hyperactivation which doesn’t mean that PARP1 is involved in active DNA repair. On the 
contrary, PARP1 hyperactivation inhibits the repair activity. PARP1 and PARG are 
responsible for balance between PAR production and degradation. Any dysregulation of 
this balance towards overproduction of PAR is detrimental to cells due to NAD+ 
overconsumption. The PARP1 hyperactivation in response to IB-DNQ induced DNA 
damage causes huge losses in NAD+ and ATP. The cells die by activating caspase 
independent programmed necrosis called NAD+ keresis. Addition of PARP1 inhibitor 
Rucaparib prevents PARP1 hyperactivation and recycles NAD+ back to NADPH which in 
turn powers more futile redox cycle creating more NQO1 – IB-DNQ mediated DNA 
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breaks, SSB to DSB conversion and finally death of cancer cells which is consistent with 
prior work [20]. This shows synergistic tumor selective action between the PARP1 
inhibitor and IB-DNQ.  
 This phosphoproteome study reveals the changes in downstream cellular signaling 
in response to different concentrations of IB-DNQ and Rucaparib. Large changes in 
phosphorylation were observed in combination therapy with low dose IB-DNQ (0.1 µM) 
and Rucaparib (15 µM) compared to the single agent Rucaparib 15 µM, 0.1 µM IB-DNQ 
and 0.4 µM IB-DNQ. The pathway enrichment using gene ontology (GO) and gene set 
enrichment analysis (GSEA) revealed expression of proteins related to the cell cycle 
checkpoint, transcription repression machinery and DNA damage. The protein-protein 
interaction analysis (PPI) showed a high level of connectivity between proteins related to 
these pathways. Various computational approaches were used to understand the protein 
network and clusters of highly interconnected proteins within the PPI.  
 To elucidate the role of different kinases involved in the phosphorylation events, 
kinase enrichment analysis was performed using a tool called KSEA. The kinases substrate 
relationship is based on the published literature from phosphosite specific databases like 
PhosphoSitePlus and NetworkIN, which uses experimental and computational information, 
respectively, for annotation. The CDK1 and CDK2 which play important role in DSB 
repair by homologous recombination by phosphorylation of BRCA1, are found in the 
downregulated area upon combination drug treatment. This prevents repair of DSB and 
increases sensitivity to PARP1 inhibitors.  Further mapping of the identified kinases from 
KSEA analysis on a kinome tree reveals upregulation in AGC and CK1 family of kinases. 
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 We also created a network topology map of the kinase substrate relationship to 
identify highly interconnected proteins or hub proteins. Any perturbation in the hub 
proteins have very large downstream signaling effects. For example, the CDK1 and CDK2 
kinases has many interactions indicating large changes due to IB-DNQ and Rucaparib 
treatment. 
 This research is also helpful in understanding protein drug interaction which 
requires further research related to systems biology and bioinformatics. Overall, the current 
study has shown that proteomic analysis is a powerful tool to understand the 
phosphorylation patterns and affected genes upon drug treatment of TNBC cells. 
 
Future Directions 
The complexity of signaling networks arises due to myriad of dynamic interactions that 
flux in time and space. There is a continuum of proteomes which interchange during 
cellular signaling process and understanding this requires a global view of the signaling 
networks to identify the systems trajectories that drives these changes. For this purpose, it 
is increasingly important to use a combination of experimental and computational models 
to understand the cellular interaction networks at systems levels and how they change the 
cell fate and behavior over time. The topological properties of the protein-protein and 
kinase-substrate interaction networks can be studied further to elucidate the directionality 
and centrality of the networks. The experimental PPI are always undirected which means 
the directionality of interactions are not provided. Here computational approaches like 
Silverbush’s algorithm [73] or machine learning algorithms can be applied to confer 
directionality to the edges in the network. Also, proteogenomics approach by integrating 
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experimental proteomic data, existing PPI information and gene expression data can be 
used to predict changes indicative of disease progression [74]. Tools like MERLIN [75] 
and SPAGI [76] can help to identify active signaling pathways by integrating gene 
expression and protein interaction data. 
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